SALT LAKE CITY - Myriad Genetics, Inc. announced that Peter D. Meldrum, president and CEO of Myriad Genetics, is scheduled to present at the J.P. Morgan 33rd Annual Healthcare Conference at 9:30 a.m. Pacific on January 12, 2015, at the Westin St. Francis in San Francisco, California.
The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriad's website at www.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad is focused on strategic directives to grow existing markets, diversify through the introduction of new products, including companion diagnostics, as well as to expand internationally. For more information on how Myriad is making a difference, please visit the Company's websites: www.myriad.com.
ISSA Introduces Healthcare Platform to Advance Safer, Cleaner Patient Environments
Third-Party Tracking Settlement is a Compliance Wake-Up Call for Healthcare Facilities Managers
ECU Health Behavioral Health Hospital Hosts Ribbon-Cutting Ceremony for New Facility
Aspire Rural Health System Reports Data Security Incident
Fatal Flaws: Strategies for Active Attackers